Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth
暂无分享,去创建一个
[1] Shihai Zhang,et al. AKAP13 couples GPCR signaling to mTORC1 inhibition , 2021, PLoS genetics.
[2] H. Hua,et al. Complex roles of cAMP–PKA–CREB signaling in cancer , 2020, Experimental Hematology & Oncology.
[3] Jenna L. Jewell,et al. Regulation of mTORC1 by Upstream Stimuli , 2020, Genes.
[4] M. Maki,et al. Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes , 2020, Journal of Biomedical Science.
[5] T. van Groen,et al. Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior , 2020, International journal of molecular sciences.
[6] M. Gurney,et al. PDE4 subtypes in cancer , 2020, Oncogene.
[7] J. Phillips. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases , 2020, Frontiers in Pharmacology.
[8] Delong Meng,et al. Glutamine and asparagine activate mTORC1 independently of Rag GTPases , 2020, The Journal of Biological Chemistry.
[9] Zhi Li,et al. High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma , 2019, Journal of Cancer.
[10] H. Hua,et al. Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.
[11] B. Manning,et al. Molecular logic of mTORC1 signalling as a metabolic rheostat , 2019, Nature Metabolism.
[12] Jinhua Zhang,et al. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy , 2019, International journal of molecular sciences.
[13] Sang-Woo Kim,et al. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer. , 2019, Biochemical and biophysical research communications.
[14] K. Guan,et al. mTOR as a central hub of nutrient signalling and cell growth , 2019, Nature Cell Biology.
[15] Susan S. Taylor,et al. GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor , 2019, eLife.
[16] Heng Li,et al. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases , 2018, Front. Pharmacol..
[17] D. Sabatini,et al. Ragulator and SLC38A9 activate the Rag GTPases through noncanonical GEF mechanisms , 2018, Proceedings of the National Academy of Sciences.
[18] W. Weis,et al. The Molecular Basis of G Protein-Coupled Receptor Activation. , 2018, Annual review of biochemistry.
[19] Xin Wei,et al. Inhibitors of phosphodiesterase as cancer therapeutics. , 2018, European journal of medicinal chemistry.
[20] Paul A. Insel,et al. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? , 2018, Molecular Pharmacology.
[21] E. Klussmann,et al. Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System , 2018, Journal of cardiovascular development and disease.
[22] Ö. Sahin,et al. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer , 2018, Clinical Cancer Research.
[23] G. Baillie,et al. PDE4-Mediated cAMP Signalling , 2018, Journal of cardiovascular development and disease.
[24] N. Pavletich,et al. Structural Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40 , 2017, Nature.
[25] N. Perrimon,et al. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. , 2017, Cancer cell.
[26] Chin-Rang Yang,et al. Systems-level identification of PKA-dependent signaling in epithelial cells , 2017, Proceedings of the National Academy of Sciences.
[27] Jenna L. Jewell,et al. Amino acid and small GTPase regulation of mTORC1 , 2017, Cellular logistics.
[28] Line Victoria Moen,et al. Evolution of the cAMP-dependent protein kinase (PKA) catalytic subunit isoforms , 2017, PloS one.
[29] Cheng Li,et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..
[30] David M. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[31] Gregory A. Wyant,et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1 , 2017, Nature.
[32] O. Brady,et al. Rags to riches: Amino acid sensing by the Rag GTPases in health and disease , 2016, Small GTPases.
[33] M. Conti,et al. PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways. , 2016, Cellular signalling.
[34] E. Kennedy,et al. Defining A‐Kinase Anchoring Protein (AKAP) Specificity for the Protein Kinase A Subunit RI (PKA‐RI) , 2016, Chembiochem : a European journal of chemical biology.
[35] Rohit Rao,et al. The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis , 2016, Cell cycle.
[36] Jia-You Fang,et al. Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies , 2016 .
[37] Yuan-Lu Cui,et al. The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review) , 2016, Molecular medicine reports.
[38] J. Blenis,et al. A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. , 2015, Current opinion in biotechnology.
[39] A. Karginov,et al. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. , 2015, Cellular signalling.
[40] Susan S. Taylor,et al. Inactivation of a Gαs-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis , 2015, Nature Cell Biology.
[41] M. Vieytes,et al. Key role of phosphodiesterase 4A (PDE4A) in autophagy triggered by yessotoxin. , 2015, Toxicology.
[42] K. Guan,et al. Differential regulation of mTORC1 by leucine and glutamine , 2015, Science.
[43] Michael N. Hall,et al. mTORC1 mediated translational elongation limits intestinal tumour initiation and growth , 2014, Nature.
[44] D. Beebe,et al. Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential , 2014, Molecular Cancer Research.
[45] L. Sapio,et al. Targeting protein kinase A in cancer therapy: an update , 2014, EXCLI journal.
[46] M. Kool,et al. The G-protein Alpha Subunit Gsα Is A Tumor Suppressor In Sonic Hedgehog-driven Medulloblastoma , 2014, Nature Medicine.
[47] D. Sabatini,et al. Regulation of mTORC1 by amino acids. , 2014, Trends in cell biology.
[48] Aurélien Rizk,et al. Segmentation and quantification of subcellular structures in fluorescence microscopy images using Squassh , 2014, Nature Protocols.
[49] C. Betz,et al. Where is mTOR and what is it doing there? , 2013, The Journal of cell biology.
[50] D. Sabatini,et al. The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. , 2013, Molecular cell.
[51] F. Zwartkruis,et al. Rheb and Rags come together at the lysosome to activate mTORC1. , 2013, Biochemical Society transactions.
[52] D. Sabatini,et al. Regulation of mTORC1 and its impact on gene expression at a glance , 2013, Journal of Cell Science.
[53] Matthew Meyerson,et al. A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.
[54] W. Seeger,et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF , 2013, Oncogene.
[55] K. Guan,et al. Amino acid signalling upstream of mTOR , 2013, Nature Reviews Molecular Cell Biology.
[56] Paolo Sassone-Corsi,et al. The cyclic AMP pathway. , 2012, Cold Spring Harbor perspectives in biology.
[57] D. Sabatini,et al. Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1 , 2012, Cell.
[58] Vassilios Ioannidis,et al. ExPASy: SIB bioinformatics resource portal , 2012, Nucleic Acids Res..
[59] C. Lugnier,et al. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments , 2012, British journal of pharmacology.
[60] H. Ke,et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases , 2012, Cell.
[61] E. Fedele,et al. GEBR‐7b, a novel PDE4D selective inhibitor that improves memory in rodents at non‐emetic doses , 2011, British journal of pharmacology.
[62] Roberto Zoncu,et al. mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase , 2011, Science.
[63] John D. Scott,et al. Discovery of cellular substrates for protein kinase A using a peptide array screening protocol. , 2011, The Biochemical journal.
[64] K. Rabe. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease , 2011, British journal of pharmacology.
[65] M. Conti,et al. PDE4D and PDE4B Function in Distinct Subcellular Compartments in Mouse Embryonic Fibroblasts* , 2011, The Journal of Biological Chemistry.
[66] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[67] D. Sabatini,et al. Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids , 2010, Cell.
[68] D. Sabatini,et al. mTOR signaling at a glance , 2009, Journal of Cell Science.
[69] F. Reimann,et al. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon‐like peptide‐1 release , 2009, British journal of pharmacology.
[70] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[71] David M. Sabatini,et al. The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 , 2008, Science.
[72] G. Baillie,et al. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. , 2007, Circulation research.
[73] Mike Tyers,et al. BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..
[74] S. Jin,et al. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. , 2005, The Biochemical journal.
[75] Joseph Avruch,et al. Rheb Binds and Regulates the mTOR Kinase , 2005, Current Biology.
[76] J. Avruch,et al. Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[77] L. Cantley,et al. Rheb fills a GAP between TSC and TOR. , 2003, Trends in biochemical sciences.
[78] K. Inoki,et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.
[79] Paul Tempst,et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. , 2003, Molecular cell.
[80] G. Livera,et al. Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling* , 2003, The Journal of Biological Chemistry.
[81] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[82] Daniel McCormick,et al. Phosphorylation of Centrin during the Cell Cycle and Its Role in Centriole Separation Preceding Centrosome Duplication* , 2001, The Journal of Biological Chemistry.
[83] M. Houslay,et al. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. , 2000, The Biochemical journal.
[84] M. Houslay,et al. UCR1 and UCR2 Domains Unique to the cAMP-specific Phosphodiesterase Family Form a Discrete Module via Electrostatic Interactions* , 2000, The Journal of Biological Chemistry.
[85] E B Cox,et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.
[86] B. Kobilka,et al. Structure and dynamics of GPCR signaling complexes , 2017, Nature Structural & Molecular Biology.